期刊文献+

托马斯液复合应用康斯特保护液对大鼠离体心肌保护作用的研究 被引量:1

Myocardial protection effects of STH solution combined with HTK solution on isolated rat hearts
暂未订购
导出
摘要 目的:观察托马斯液(STH)复合应用不同剂量康斯特保护液(HTK)对大鼠长时间缺血心肌的保护作用。方法:雌性Wistar大鼠40只,体重230~280g,随机分为S、H、S+H10、S+H20和S+H30共5组(n=8)。麻醉后开胸取出心脏立即连于langendorff灌注装置,制备心脏缺血再灌注模型,S组用STH液15ml/kg每30min灌注1次,H组用HTK液30ml/kg单次灌注,其余3组均先用STH液15ml/kg灌注后分别续灌HTK液10ml/kg、20ml/kg、30ml/kg。分别留取停搏前、再灌注15、30min时冠脉流出液2ml用于检测心肌乳酸脱氢酶(LDH)、肌酸激酶(CK)。实验末留取心尖部心肌组织,用于检测心肌组织三磷酸腺苷(ATP)、丙二醛(MDA)、超氧化物歧化酶(SOD)含量。结果:与S组比较,其余4组复灌15、30min后冠状动脉流出液心肌酶CK、LDH含量较低(P<0.05,P<0.01);与S、H、S+H10各组相比,复灌30min后,S+H20组及S+H30组心肌ATP、SOD含量增高(P<0.05,P<0.01),心肌MDA含量降低(P<0.05,P<0.01)。结论:STH液复合一定剂量的HTK液诱导并维持心脏停搏能增加大鼠离体心肌ATP、SOD含量,降低MDA含量,减轻缺血再灌注损伤。 Objective: To observe myocardial protection effects of STH solution combined with HTK solution on isolated rat hearts after long time ischemia. Methods: 40 female Wistar rats, weight 230-280 g, were randomized as 5 groups : group S; group H; group S +H10; group S +H20 and group S +H30. Langendorff ischemic-reperfusion model was developed by isolated rat after anesthesia, group S and group H was perfused with STH solution 15 ml/kg every 30 minutes or HTK solution 30 ml/kg once time, in the other 3 groups, STH solution was perfused as 15 ml/kg at first, then perfused with HTK solution 10 ml/kg, 20 ml/kg,30 ml/kg respectively. 2 ml of coronary flow was taken before the cardiac arrest and after reperfused 15 min, 30 min to detect myocardial leak enzyme LDH, CK. Tissue at heart apexes was retented after experiment. ATP, MDA and SOD contents in myocardium were detected. Results:Compare with group S, the content of CK and LDH was lower in the other 4 groups (P〈0.05,P〈0.01); after reperfused 30 min, the content of ATP, SOD was increased significantly in group S+H20 and S+H30, yet the content of MDA was decreased (P〈0.05,P〈0.01). Conclusion: STH solution combined with certain dosage of HTK solution to induce and maintain the cardiac arrest can increase the content of ATP,SOD ,decrease the content of MDA in vitro rat myocardium and mitigate the ischemic-reperfusion injure.
出处 《天津医科大学学报》 2009年第4期659-662,674,共5页 Journal of Tianjin Medical University
关键词 HTK液 STH液 大鼠 心肌保护 离体 HTK solution STH solution Rat Myocardium protection Vitro
  • 相关文献

参考文献8

二级参考文献20

  • 1孙彩霞,高春霖,薛玉良,冯雪辛,张永强,顾书华.左旋卡尼汀对大鼠心脏缺血-再灌注损伤能量代谢的影响[J].天津医药,2005,33(12):783-785. 被引量:15
  • 2谢江,曾秋棠,王乐.The Protective Effect of L-carnitine on Ischemia-reperfusion Heart[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2006,26(2):188-191. 被引量:10
  • 3汪源,舒涛,杨楚墩等.Bretschneider心肌保存液临床应用20例报告[J].体外循环杂志,2002,(4):44-45.
  • 4[3]G Careaga,D Salazar,S Téllez,et al.Clinical impact of histidine-tryptophan - ketoglutalate (HTK) cardioplegic solution on the perioperative period in open heart surgery patients [J].Arch Med Res,2001,32:296 - 299.
  • 5[4]Sakata JI,Morishita K,Ito T,et al.Comparison of clinical outcome between histidine -tryptophan -ketoglutalate solution and cold blood cardioplegic solution in mitral value replacement[J].J Card Surg,1998,13:43 -47.
  • 6[5]Hachida M,Nonoyama M,Bonkohara Y,et al.Clinical assessment of prolonged myocardial preservation for patients with a severely dilated heart[J].Ann Thorac Surg,1997,64:56-59.
  • 7[1]Engelman RM ,Levitsky S.A textbook of Cardioplegia for Difficult Clinical Problems[J].Mount Kisco,NY ,Futura Publishing Company,Inc,1992:203.
  • 8[2]Jakob VJ.Myocardial Protection:An Overview[J].J Extra Corpor Technol,2000,32:38 - 47.
  • 9[3]Gebhard MM,Bretschneider HJ,Gersing E,et al.Calciumfree cardioplegia[J].Euro Heart J,1983,4 (Supplement H),151 - 160.
  • 10[4]Martin J,Lutter G,Ihling C,et al.Myocardial viability twentyfour hours after orthotopic heart transplantation from non - heartbeating donor[J].J Thorac Cardiovasc Surg ,2003,125:1217.

共引文献16

同被引文献15

  • 1邢家林,龚庆成,李蔚然.康斯特保护液与其它心脏停搏液心肌保护作用比较[J].中国体外循环杂志,2006,4(1):5-8. 被引量:11
  • 2司忠义,郭宁.康斯特保护液与晶体或含血停搏液的作用比较[J].中国体外循环杂志,2006,4(1):16-17. 被引量:5
  • 3Cao C, Yang M, Wang G, et al. Excision of atrial myxoma u_sing robotic technology [ J]. J Tliorac Cardiovasc Surg, 2010,139(5): 1282-1285.
  • 4Careaga G, Salazar D,T6llez S, et al . Clinical impact of histi-dine -ketoglutarate - tryptophan ( HTK) cardioplegic solutionon the perioperative period in open heart surgery patients [ J].Arch Med Res, 2001,32(4) ; 296 - 299.
  • 5Saitoh Y, Hashimoto M,Ku k, et . Heart preservation inHTK solution : role of coronary vasculature in recovery of cardi-ac function[ J]. Ann Thorac Surg, 2000 , 69( 1) :107 -112.
  • 6Arslan A, Sezgin A, Cultekin Bf et al. Low - dose histidine-tryptophan - ketoglutarate solution for myocardial protection[J]. Transplant Proc, 2005 , 37(7): 3219-3222.
  • 7Liu J, Feng Z, Zhao T, et al. The myocardial protection ofHTK cardioplegic solution on the long 一 term ischemic periodin padiatric heart sui^ery[ J]. ASAIO J,2008 , 54(5) : 470-473.
  • 8Ckouziouta A, Adamopulos S, Manginas A, et al. Hearttransplantation in a low - organ _ donation environment : Asingle center experience [ J]. Transplant Proc, 2009 , 41(10): 4289 - 4294.
  • 9张文静,薛玉良.含血停搏液及其联合康斯特保护液的作用比较[J].天津医科大学学报,2008,14(4):501-503. 被引量:4
  • 10宋怡,李华,杨鸿生,张桂敏,蔡冰.康斯特保护液对紫绀型先天性心脏病未成熟心肌保护效果的临床研究[J].中国体外循环杂志,2009,7(1):23-25. 被引量:11

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部